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Abstract
The increasing interest and recent developments in nanotechnology pose previously unparalleled challenges in understanding the
effects of nanoparticles on living tissues. Despite significant progress in in vitro cell and tissue culture technologies, observations
on particle distribution and tissue responses in whole organisms are still indispensable. In addition to a thorough understanding of
complex tissue responses which is the domain of expert pathologists, the localization of particles at their sites of interaction with
living structures is essential to complete the picture. In this review we will describe and compare different imaging techniques for
localizing inorganic as well as organic nanoparticles in tissues, cells and subcellular compartments. The visualization techniques
include well-established methods, such as standard light, fluorescence, transmission electron and scanning electron microscopy as
well as more recent developments, such as light and electron microscopic autoradiography, fluorescence lifetime imaging, spectral
imaging and linear unmixing, superresolution structured illumination, Raman microspectroscopy and X-ray microscopy. Impor-
tantly, all methodologies described allow for the simultaneous visualization of nanoparticles and evaluation of cell and tissue
changes that are of prime interest for toxicopathologic studies. However, the different approaches vary in terms of applicability for
specific particles, sensitivity, optical resolution, technical requirements and thus availability, and effects of labeling on particle
properties. Specific bottle necks of each technology are discussed in detail. Interpretation of particle localization data from any of
these techniques should therefore respect their specific merits and limitations as no single approach combines all desired properties.
Beilstein J. Nanotechnol. 2015, 6, 263–280.
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Introduction
In the rapidly growing field of nanotechnology, recent develop-
ments have yielded a plethora of different nanoparticles (NP)
with novel size-dependent properties that are very distinct from
those of their bulk material [1,2]. On the one hand, the poten-
tial advantages of NP in biomedical research are manifold. For
example, nanomaterials find application in surgical implants to
improve tissue formation or due to their antibacterial action,
they may be useful for gene or drug delivery systems as well as
diagnostic imaging tools [3-7]. On the other hand, due to the
entirely new properties of NP, the risk of adverse and even toxic
side effects as well as accumulation of NP in the body has to be
considered [1,5]. Clearly, the mentioning of all current medical
applications, developments and future visions on NP tech-
nology is by far beyond the scope of this review and excellent
review articles are available on NP pharmacology and toxi-
cology in humans and animals [8,9]. However, despite all
advancements in in vitro testing including permanent or prima-
ry cell lines and ex vivo organ cultures, the complexity of a
living organism cannot be modeled in a test tube or culture dish.
In this regard, similar to the assessment of effects of bulk ma-
terial compounds, the microscopic assessment of expert pathol-
ogists is indispensable for the identification and characteriza-
tion of target cells and structures as well as for the effects on
and responses by these structures. For example, unfavorable
tissue reactions directly induced by NP have to be monitored,
such as degeneration and necrosis of target structures,
NP-induced inflammation with influx and activation of immune
cells, tissue fibrosis or even the induction of tumor growth
[2,10,11]. Moreover, if the NP are destined for diagnostic or
therapeutic applications in diseased tissue, the disease environ-
ment needs to be taken into account, either in terms of the
effects of NP on the course of the disease or in terms of effects
of the disease on the distribution and behavior of NP. For
example, several studies have suggested an aggravation of
allergic disease models following exposure with silica nanopar-
ticles (SiO2-NP) [12-14]. Inorganic SiO2-NP hold great poten-
tial for several biomedical applications, including the selective
targeting of cancer cells as well as drug or gene delivery
systems due to their favorable biocompatibility and modifica-
tion possibilities [15,16]. However, other authors have failed to
see an aggravation of disease. In some cases, they even reported
an alleviation of skin lesions following exposure with SiO2-NP
or zinc oxide NP (ZnO-NP) [17,18]. ZnO-NP and titanium
dioxide NP (TiO2-NP) are major ingredients of sunscreens [19]
and their toxicity is of prime interest in the safety evaluation of
NP. Importantly, for a precise understanding of the biological
and toxicological effects of complex NP it is important to
understand which part of the NP induces the observed effects,
e.g., the inorganic core, the ligand shell, the protein corona or
even the drug or label inside or associated with the particle.
Therefore, more sophisticated imaging methods are needed that
allow one to distinguish different parts of a NP within tissues or
cells. Furthermore, the expertise of specially trained toxicolog-
ical pathologists is essential in any multidisciplinary team
involved in the development, characterization, and risk assess-
ment of novel NP [20]. For this purpose, professional training
and standardized certification of toxicological pathologists are
firmly established, for example, by the European or American
Colleges of Veterinary Pathologists [21-23] and specialization
as well as continuing professional development are embedded
in professional organizations such as the Society of Toxico-
logic Pathology (STP) in Europe, ESTP, or its US counterpart
[21,24]. Today, the assessment of tissue and whole organisms
through expert pathologists is essentially involved in the entire
process of NP research and development, ultimately culmi-
nating in preclinical and clinical studies requested by regula-
tory authorities [25-27].
For a comprehensive understanding of the effects of NP in
normal and diseased tissues, knowledge about their target struc-
tures, local and systemic NP distribution after administration
and their final destination is indispensable. For an optimal
pathological assessment, it is thus desirable to combine imaging
techniques for the visualization of NP with techniques that are
classically used for pathological examination of tissue sections
from single organs and entire organisms. For this purpose, the
light microscopic examination of approximately 5 µm thick
sections of formalin-fixed and paraffin embedded (FFPE) tissue
samples has proven indispensable for many decades [28-30].
However, many methodologies that have been used to localize
or quantify NP, including elemental analyses by methods such
as inductively coupled plasma atomic emission spectroscopy
(ICP-AES) or atom absorption spectroscopy (AAS), require
lysis, separation or homogenization of the cells and tissues
[28,31,32]. The resulting consequence is a complete and irre-
versible loss of information about the association with or reac-
tions by adjoining vital structures, making such approaches
unfavorable for the purpose of concomitant pathological tissue
assessment. Moreover, using antibody-based methods, the
molecular phenotype in certain tissues can be interpreted within
the biological context [33].
In this overview, we introduce and compare different imaging
techniques for localizing inorganic NP like silica and iron oxide
NP as well as organic NP such as polymer dendritic poly-
glycerol sulfates (dPGS) and chitosan NP. Importantly, all tech-
niques described can be used for the simultaneous visualization
of NP and toxicopathological assessment of the putative
uptaking cells and adjacent tissues. All methodologies presented
here should fulfill the following criteria: The techniques should
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be applicable for a pathologist in a more or less high-throughput
manner, they should allow for a visualization of NP with
concurrent evaluation of medically relevant tissue changes and
they should be economic and practical for many samples. We
describe well-established and widely used techniques, such as
light, fluorescence, transmission electron and scanning electron
microscopy which have already been reviewed by others from a
different angle [20,34,35]. Furthermore, we will highlight and
introduce new and more advanced techniques including light
and electron microscopic autoradiography, fluorescence life-
time imaging, spectral imaging and linear unmixing, superreso-




Light microscopic examination has become the gold standard of
pathologic evaluation and risk assessment of drugs and
nanoparticles during the past 50 years. This technology uses
sections of 3 to 8 µm thickness from FFPE or cryosectioned
tissue samples, usually stained with hematoxylin and eosin
(HE). As a required but well accepted simplification, two-
dimensional (2D) images of a complex three-dimensional (3D)
biologic structure are analyzed. Standardized trimming proto-
cols help to reduce interregional variations and increase the
reproducibility and comparability of toxicopathologic studies
[25,36-38]. Light microscopy thus allows for a sensitive, effi-
cient, and cost-effective evaluation of large amounts of micro-
scopic information and largely satisfies demands by regulatory
authorities [25]. In the past years, this technology has also
proven useful in characterizing toxicological effects of various
NP by histopathological examinations of large numbers of
diverse tissues and organ systems [39-42].
The ideal setup would allow for NP detection and evaluation of
surrounding tissue at the same time. Nevertheless, a certain
magnification must be achieved for the detection of nanoparti-
cles in the tissue due to their size of, by definition, less than
100 nm [20]. Single particles thus cannot be resolved due to the
maximal diffraction limited resolution of 200 to 500 nm at
highest light microscopic magnification. Thus, only NP that
cluster or form aggregates of more than 200 nm in size in the
tissue of interest can be visualized directly. In addition, these
aggregates have to be able to attenuate visible light to be
detectable by using light microscopy. For example, carbon
nanotubes (CNT) used in medical or electronic devices that are
known to induce granuloma formation and fibrosis in the lung
following intratracheal exposure appear as grey structures when
forming aggregates in tissue sections stained according to stan-
dard protocols [43,44]. Aggregated iron oxide nanoparticles are
visible as brown deposits in HE-stained sections of glioblas-
tomas (Figure 1a), a common brain tumor with high clinical
relevance [45]. Such particles have similarly been visualized
after targeting prostate cancer cells in humans [46]. Iron oxide
nanoparticles have been introduced as diagnostic tool or for the
treatment of various cancers [45-48]. In several applications,
they have proven to possess excellent tumor-targeting efficacy
[49]. Likewise, titanium dioxide nanoparticles, essential compo-
nents of sunscreens, were visualized as yellow-brown particles
on superficial stratum corneum layers in HE-stained skin
samples following topical application [29].
In addition, specific characteristics of some NP may be used to
visualize them through so-called special stains that have been
developed by pathologists over many decades. Aggregates of
the above mentioned iron oxide NP, for example, may be
stained by several special stains for iron (Figure 1b), including
Turnbull blue and Prussian blue [45,48,50], which are usually
used to label pigments containing biogenic iron, such as hemo-
siderin [51]. Alcian blue is a histologic stain for the detection of
negatively charged sulfate groups that occur, for example, in
mucins [52,53]. The organic dendritic polyglycerol sulfate
(dPGS) NP possess a complex, branching structure of poly-
glycerol residues with such negatively charged sulfate groups in
their shells [54]. Several studies have suggested promising ther-
apeutic and diagnostic potential for dPGS, including anti-
inflammatory effects with rather specific accumulation in
inflamed tissues [55-57]. Due to their sulfate groups and the
specific staining properties of Alcian blue, this method has been
used successfully, for example, for the detection of dPGS amine
accumulated in Kupffer cells in the liver of mice following
intravenous injection (Figure 1c) [56,58]. As a third example of
NP detectability in tissues, single-walled CNT labeled by cova-
lent binding of colloidal gold can be visualized through light
microscopy by using silver enhancement [59]. In this method,
the colloidal gold serves as a nucleation core for metallic silver.
The silver layer formed around the gold core increases the
particle size dramatically and imparts a black color when
viewed by light microscopy [60]. However, any labeling of NP
may possess the risk of changing their physicochemical charac-
teristics and their bioreactivity [20]. Accordingly, previous
studies have shown that surface modifications by additional
molecular labels may significantly influence the physical and
chemical properties of NP, thereby also altering their behavior
in cells and tissues as well as toxicologically relevant responses
[35], an effect that will be discussed in more detail below.
Light and electron microscopic
autoradiography
Autoradiography is based on the spatiotemporal recording of
radioisotopic decay in the context of surrounding tissues. It has
been used to provide an overall picture of the systemic distribu-
Beilstein J. Nanotechnol. 2015, 6, 263–280.
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Figure 1: Nanoparticles may be detected through light microscopy by
using chemical staining protocols that are conventionally employed in
histopathology. For example, clusters of iron oxide nanoparticles can
be visualized in HE-stained tissue sections as a finely granular brown
material within the cells of a glioblastoma tumor (a, with kind approval
of MagForce AG, Berlin, Germany). When serial sections from the
same tissue were stained with a canonical stain for iron, Turnbull blue,
the particles appear dark blue (b). As a second example, Alcian blue
stain may be used to stain dendritic polyglycerol sulfates (dPGS) due
to their negatively charged, sulfate rich shell. Organic dPGS amine
accumulated in the cytoplasm of hepatic Kupffer cells (c, arrow). These
liver specific macrophages are identified by their comma-shaped nuclei
and their lining of hepatic sinusoids. Adjacent hepatocytes (c, aster-
isks) appear as light pink cells with finely stippled cytoplasm whereas
erythrocytes within sinusoids can be identified by their intensely pink
color.
tion of radiolabeled drugs or NP and even allows for a semi-
quantitative assessment of NP in tissues [61,62]. Various
radioisotopes, including those of silver (110mAg), carbon (14C)
or indium (111I) have been used to label NP and to study their
distribution throughout the whole body [63-65]. Radiation from
these isotopes is usually detected and quantified by a gamma
counter, micro imager, phosphoimager plates or autoradio-
graphic films that are commonly used for X-ray exposures.
However, such autoradiographs performed on cross sections of
whole bodies or total organs of animals (Figure 2a and
Figure 2b) [62,63,66-68] possess optical resolution limited to
around one millimeter and fail to provide information on the
cell or tissue levels [61].
In contrast, the optical resolution of light microscopic autoradi-
ography (LMA) using photoemulsion-covered histological
slides is limited by the optical resolving power of the light
microscope (0.2 µm) and the grain size of the emulsion [69].
This technique has previously been used, for example, for the
localization of specific nucleic acid sequence, e.g., chromo-
somes or viral infections, by in situ hybridization employing
radiolabeled nucleic acid probes [70]. We reasoned that this ap-
proach could also be useful in detecting radiolabeled NP at light
microscopic resolution and established a method for the visual-
ization of dPG35S amine NP in pathohistologic slides
(Figure 2c) [56,58]. The 35S-labeling of dPGS amine appears
particularly suitable since the radioisotope replaces “cold”
sulfur atoms in the outer shell of the NP, without changing its
size, molecular weight or other biologically relevant physical or
chemical properties [58]. Following intravenous application of
dPG35S amine into mice, HE-stained FFPE tissue sections from
various organs were covered with an autoradiographic emul-
sion. The slides were exposed for several days and finally fixed
with a commercially available fixator for photographic films
[56]. Autoradiography can also be adjusted for electron
microscopy, EMA, by selecting emulsions with more appro-
priate grain diameter, tracking characteristics and sensitivities
[71]. Both LMA and EMA offer high sensitivity due to the
possibility of long exposure times with even small amounts of
radioactive decay being detectable [56,58,72]. Importantly, after
counterstaining the same slides with standard histostains,
such as HE, routine pathohistologic examination of the same
tissue is possible in direct context of the autoradiographic NP
signals [56].
Fluorescence microscopy
Conventional fluorescence microscopy is an essential tool in
countless biomedical research applications and possesses a
resolution similar to that of bright-field light microscopy
[35,73]. As a consequence, NP can only be detected when they
are closely clustered in aggregates or densely packed, for
Beilstein J. Nanotechnol. 2015, 6, 263–280.
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Figure 2: Autoradiographic detection of radiolabeled dPG35S amine in
organs and tissues. (a) Semiquantitative micro imager analysis
detected different amounts of dPG35S amine in mouse organs,
decreasing from the kidney over the liver and the spleen to the heart
one hour after intravenous injection (top panel: counting rates with
regions of interest (indicated by red lines); bottom panel: combination
of optical image and counting rates). (b) Single organ autoradiography
of mouse kidney (left panel) and spleen sections (right panel) on X-ray
film following dPG35S amine application identified distribution patterns
of the radiolabeled NP in accordance with organ specific functional
structure. In the kidney, NP were localized within the renal cortex
(outer rim) whereas in the spleen they were clearly associated with the
red pulp but not within lymphoid follicles (spared dots). (c) Light micro-
scopic autoradiography with numerous radioactive decay-induced
signals over Kupffer cells (arrows) in the liver of a mouse (left panel).
Signals were sparse in adjacent hepatocytes with larger, more round
nuclei. No signals were observed when unlabeled dPGS amine was
used under otherwise identical experimental conditions (right panel).
Hematoxylin and eosin-stained FFPE tissue sections.
Figure 3: Aggregates of FITC-labeled SiO2-NP (green, 55 ± 6 nm in
diameter) were visualized by fluorescence microscopy in macrophages
following subcutaneous injection (a). Nuclei were counterstained with
DAPI (blue). Subsequent immunofluorescent labeling (red) for the
macrophage marker F4/80 identified macrophages as uptaking
cells (b).
example, in phagocytic vacuoles. Pathologists routinely employ
methods of fluorescent labeling for immunofluorescence, i.e.,
antibody-based identification of specific cell types, cell acti-
vation statuses, and apoptotic or degenerative changes [74]. In
addition, fluorescence microscopy has been widely used in
studies on the biodistribution of nanoparticles [28,48,75-78].
For fluorescence microscopic detection, NP are usually labeled
with fluorescent dyes, such as fluorescein isothiocyanate (FITC)
and indocarbocyanine. Several classes of NP have been local-
ized after addition of such tags, including silica nanoparticles
(SiO2-NP, Figure 3a) [28,75,79-81] and dPGS [82]. Inorganic
SiO2-NP hold great potential for several biomedical applica-
tions, including the selective targeting of cancer cells as well as
drug or gene delivery systems due to their favorable biocompat-
ibility and modification possibilities [15,16]. However, labeling
of NP always possesses the risk of changing their bioreactivity
[20]. Thus, the site of labeling and the properties of the fluo-
Beilstein J. Nanotechnol. 2015, 6, 263–280.
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rochrome may have to be considered when predicting the
altered physicochemical properties of the labeled NP, including
its charge, size, molecular weight, and overall structure [35].
For example, integrating indocarbocyanine-3 with a molecular
weight of 767 Da into nanoscaled macromolecules such as
dPGS with a molecular weight of 1,300 Da [56] can be
expected to drastically alter its physicochemical properties [56].
Consequently, if fluorochromes are integrated into the shell or
bound to the surface of a NP, the properties of the new struc-
ture are hard to predict and may even alter its behavior in cells
and tissues when compared to unlabeled particles [35]. In
contrast, incorporation of the dye into the core of an otherwise
unaltered surface of a NP may leave its overall properties
unchanged, especially when an unlabeled shell can be grown
around this core. In addition, the potential of additional specific
surface functionalization and binding of other molecules of
interest may remain completely similar to that of unlabeled
particles [79,83,84].
Another disadvantage when using fluorescent dyes is their time-
dependent photobleaching, which results in a more or less rapid
fading of the fluorescent yield [85]. In this regard, the increased
brightness and photostability of a fluorescent dye when incorpo-
rated into the core of SiO2-NP are particularly welcome [83].
Of note, some specifically engineered NP may hold inherent
fluorescent properties, such as inorganic quantum dots (QD)
[76]. QD used in bioapplications are typically composed of a
semiconductor core (e.g., cadmium sulfide), an outer shell of a
higher band semiconducting material (e.g., zinc sulfide) and a
surface functionalization which may consist of various hydro-
philic organic molecules including biomolecules or polymers
[86]. QD with their size-dependent optical properties possess
great potential as probe for biomedical imaging applications, as
previously shown for the mapping of lymph node structures
[87]. Their superior photostability, their broad excitation and
narrow emission spectra offer additional advantages [85] that
even allow for the detection of mixed QD populations with a
single excitatory wavelength [86]. Furthermore, the impact of
toxic ions released by QD on biological matter has been mini-
mized by embedding QD into silica nanoparticles [88] without
influencing the optical properties [89]. Unlike fluorescent dyes
that undergo photobleaching, photoactivation is a remarkable
property of QD enhancing their quantum yield over time [90].
Another group of highly photostable NP are lanthanide-doped
upconversion NP (UCNP). Upconversion is an optical process
in which the sequential absorption of two or more photons leads
to the emission of light at shorter wavelength than the excita-
tion wavelength [91]. UCNP feature a reduced cytotoxicity
compared to QD and are, in contrast to fluorescent dyes or QD,
excited by near infrared (NIR) light. By using long-wavelength
NIR instead of ultra violet (UV) light, background autofluores-
cence typically caused by collagen and other autofluorescent
structures of tissues is dramatically reduced [92]. NIR light
penetrates deeper into biological tissue and thus in vivo tracking
of UCNP holds promising applications [93]. The properties,
synthesis as well as options of modifications and applications of
UCNP have been reviewed recently [92,93]. Due to the low
autofluorescence of tissues in NIR imaging, it has been success-
fully used for in vivo visualization of various other NP [94,95].
However, in vivo imaging may demonstrate the dynamic
process of NP distribution but suffers from a poor spatial reso-
lution [96]. Alternatively, high-resolution in vivo imaging of
NP commonly requires more invasive methods [20,97].
One important drawback of fluorescence microscopy is the lack
of visibility of other structures without fluorescent properties
such as normal cells, membranes, and nuclei. The concurrent
counterstain of nuclei with the blue fluorescent dye 4',6-
diamidino-2-phenylindole (DAPI), for example, may overcome
this disadvantage by allowing a view of all nucleated cells
within the tissue. However, the selective counterstaining of
nuclei only provides information on nuclear size, shape, and
location which is insufficient for a complete histological assess-
ment by a pathologist. Another approach is to compare and
merge images of fluorescence microscopy and bright field
microscopy by illuminating the same slide and location used for
fluorescence microscopy with transmitted light [20,77].
As a further methodological option, fluorescent detection of NP
can easily be combined with the immunofluorescent labeling of
marker proteins which, for example, enable simultaneous iden-
tification of specific cell types, tumor markers, and even infec-
tious agents [20]. In this combination, nanoparticles can even be
spatially co-localized with marker proteins that help to identify
both the uptaking cell type and its activation status (Figure 3b)
[50,75,83]. Optical resolution of such co-localizations may be
increased by various technical refinements, including confocal
laser scanning microscopy which allows for serial 2D optical
sectioning of the slide and even 3D reconstructions of complex
tissues and single cells [98].
Fluorescence lifetime imaging microscopy
(FLIM)
Fluorescence lifetime imaging microscopy (FLIM) is a highly
innovative and promising method which has been recently used
in various biomedical and life science applications but not in
routine toxicopathology so far. FLIM setups usually combine
conventional laser scanning confocal microscopy with time-
correlated single photon counting, thus, enabling the recording
of fluorescence lifetime decay traces for each pixel. The fluo-
rescence lifetime decay curve represents the excited-state decay
Beilstein J. Nanotechnol. 2015, 6, 263–280.
269
Figure 4: Discrimination of fluorescein isothiocyanate (FITC) labeled SiO2-NP (55 ± 6 nm in diameter) from the autofluorescent background of skin
and subcutaneous tissue using fluorescence lifetime imaging microscopy (FLIM). False color coded sections of mouse skin including subcutis
following subcutaneous particle injection from the site of injection (+SiO2-NP, (a)) and from the contralateral without NP (b) are presented. Cyan
colored areas represent the autofluorescent background, while the yellow colored areas indicate a different lifetime species, which was identified as
FITC-SiO2-NP. Scale bar = 50 µm. (c) Fluorescence lifetime curves of the tissue autofluorescence (mean lifetime curve) and of the FITC-SiO2-NP.
behavior of a fluorochrome, usually decaying within the
nanosecond range [99], and can be approximated by a single or
a sum of several exponential functions [100,101]. A major
advantage of FLIM is that the influence of the local environ-
ment of the fluorochrome can be monitored independently of
the fluorochrome concentration [102].
FLIM gains its information from the fluorescence decay curves
and applications of this technique include environmental
sensing of, amongst others, polarity, local pH, and calcium
concentrations, as well as the study of protein interactions in
living cells [102]. FLIM image analysis allows for a fast and
reliable localization of target molecules, e.g., fluorochromes,
against autofluorescent background [82,103]. FFPE tissue
sample analysis in standard histopathologic examinations is
often complicated by autofluorescence. The phenomenon of
autofluorescence by endogenous fluorophores, e.g., NAD(P)H,
collagen, melanin, and keratin [104] or due to tissue prepar-
ation artifacts may result in difficulties to distinguish a fluores-
cent signal yielded by fluorochromes from autofluorescence
with conventional color cameras [105]. The discrimination of
NP against the background has recently been shown for zinc
oxide NP [106] as well as indocarbocyanine (ICC)-labeled
core–multishell nanoparticles [107] in the skin, indocarbocya-
nine-labeled dPGS in the liver [82] and for subcutaneously
injected silica-based NP (Figure 4) [81]. Recent developments
of both hard- and software have further contributed to the
advancement of FLIM [102] that seems to hold great potential
for its use in a number of biomedical applications, for example,
as diagnostic tool for histopathology [99].
Spectral imaging and linear unmixing
Spectral imaging combined with linear unmixing is another
technique that is not commonly used by pathologists to date but
widely used in biomedical research. Similar to FLIM, it can be
used on FFPE tissue sections to distinguish a fluorescent signal
of fluorochromes from autofluorescence.
Whole emission spectra of the fluorescent signals are generated
from a slide by using a multidetector array (Figure 5) [108]. In
this approach, the generated emission spectrum of a certain dye
used as label for NP differs unequivocally from the emission
spectra generated by autofluorescent signals [109] and can be
identified by using spectral libraries [33]. Moreover, this tech-
nique allows for the use of multiple fluorescent labels that
cannot be distinguished in conventional fluorescence micro-
scopic setups due to overlapping emission spectra [110]. Thus,
multiple fluorescent labels may be used in a single slide to
study interactions of cells and subcellular constituents in detail
[110]. Spectral imaging and unmixing offers substantial
improvement in signal-to-noise ratio and image contrast
compared to the use of monochrome band-pass emission filters
as employed in conventional fluorescence microscopes [111].
This approach also facilitates the detection of signals that are
otherwise masked by autofluorescence [33]. For example,
recent developments in the immunotherapy of tumor cells
require a multimarker-based phenotyping and spectral imaging
with subsequent unmixing appears to be valuable for the identi-
fication of tumor phenotypes within a single FFPE tissue slide
[111,112]. Such data can even be analyzed automatically by
using specialized software [112].
So far, spectral imaging with linear unmixing has only been
used for the localization of QD as advanced fluorescent label
with a narrow emission bandwidth [109,113]. However, for
biodistribution and subcellular localization studies of fluores-
cently labeled NP, the spectral imaging and linear unmixing
technique may become valuable in future work on the biodistri-
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Figure 5: Spectral imaging and linear unmixing detection of green fluorescent SiO2-NP (55 ± 6 nm in diameter) in the subcutis of a mouse, indicated
by the red cross (a), revealed an emission curve (b) which is highly specific for FITC with an emission maximum between 520 and 530 nm
wavelength.
bution of NP in the context of entire tissues. So far, one study
reported the in vivo distribution of QD following various appli-
cation routes and sites but more data are required [114].
Despite the huge potential of spectral imaging in the patholog-
ical examination, it would be desirable that advances in soft-
ware and hardware as well as reagents will lead to a wider use
of this technique in routine toxicopathologic examinations [33].
Superresolution structured illumination
microscopy (SR-SIM)
The optical resolution of fluorescence microscopy of approxi-
mately 200 nm has recently been increased twofold by superres-
olution structured illumination microscopy (SR-SIM)
[115,116]. By rotating an optical grating and multiplication of
the obtained pattern, so-called moiré fringes can be seen as
stripes in the overlapping regions. These moiré fringes contain
information about the unknown structure and the observer gains
access to normally unresolvable information in the sample
[115]. Thus, multiple images with different phases and orienta-
tions of the patterned light are recorded and reconstructed to
obtain the SR-SIM image [117]. A detailed description on the
principles of this technique was recently published elsewhere
[118]. Moreover, the out-of-focus light is rejected computation-
ally [119]. However, SR-SIM has not yet become a standard
technique for histopathological examinations. It is primarily
used for detailed analysis of subcellular structures, such as the
cytoskeleton [115]. Importantly, this technique also allows for
3D reconstructions of information within the cell at a higher
resolution level with all additional advantages described for
confocal laser scanning microscopy [119,120].
Of note, conventionally prepared slides can be used for SR-SIM
and no special preparation is required [121]. We used this tech-
nique to localize FITC-labeled SiO2-NP in FFPE tissue sections
of mice that were sliced and dewaxed according to standard
protocols. The dewaxed, unstained slides were covered with
Roti-Mount FluorCare (Carl Roth GmbH, Karlsruhe, Germany)
and examined with the ELYRA PS.1 inverted microscope
combined with a confocal laser scanning microscope LSM 780
(both microscopes from Carl Zeiss, Jena, Germany). A z-stack
over a distance of 4.49 µm consisting of 42 images was scanned
on an area of 970 × 970 pixels. The images were subsequently
processed by using a ZEN system 2012 (Carl Zeiss) and
exported by using the ZEN lite software. When the images were
compared with images obtained by wide-field fluorescence
microscopy SR-SIM images were clearly superior due to higher
resolution and less blurry appearance (Figure 6).
Of note, SR-SIM requires highly stable fluorochromes to
achieve high quality images. Photobleaching of the fluo-
rochrome after prolonged excitation time and high laser inten-
sity necessary for SR-SIM may thus cause limitations in the
reconstruction of the images [122,123]. However, the SR-SIM
requires up to 106-fold lower illumination intensities compared
to single-molecule imaging or other superresolution approaches
[119]. Other superresolution techniques including structured
illumination have been used to study NP, such as QD due to
their favored optical properties [122,124,125] and in investi-
gations on the architecture of specific NP [117].
Raman microspectroscopy
Raman microspectroscopy provides high-resolution imaging
combined with chemical analysis without destruction of the bio-
logical sample and the use of labels [126-128]. Intrinsic chem-
ical bond vibrations can be visualized and characterized
combined with optical sectioning with diffraction-limited
spatial resolution that can be approximated to 1 µm [129,130].
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Figure 6: FITC-labeled SiO2-NP (55 ± 6 nm in diameter) within a
single SiO2-containing cell of the subcutaneous tissue visualized by
conventional widefield (a) versus superresolution structured illumina-
tion microscopy (b). Red circles indicate nuclei, white outlines indicate
outer cell borders. FFPE subcutaneous tissue sections from mice
following subcutanous injection of FITC-labeled SiO2-NP were sliced
and dewaxed according to standard protocols. The dewaxed,
unstained slides were covered and observed with the ELYRA inverted
microscope (Carl Zeiss, Jena, Germany). The comparison of the
conventional wide field image (a) and superresolution structured illumi-
nation image (b) yields a clearer and less blurry image of clustered
FITC-labeled SiO2-NP.
This technique has been used, for example, in in vivo and diag-
nostic imaging of various cancers in humans [131]. Margins
between normal and pathological tissue can be determined
based on biochemical spectra [132]. Furthermore, Raman
microscopy can be used to track NP inside cells and at the same
time provides information on biochemical interactions within
the cell [126]. However, one disadvantage is that only low
signal intensities are emitted by biomolecules themselves [132].
Advanced Raman techniques, such as surface-enhanced Raman
spectroscopy (SERS), coherent anti-Stokes Raman spec-
troscopy (CARS), and stimulated Raman spectroscopy (SRS)
have been used in the past along with microscopy approaches
for studying biological matter along with nanoscopic systems
[133-136]. Moreover, NP may be used as specific SERS-label
which was coupled to the primary antibody for the immunohis-
tochemical detection of proteins in tissue sections. Thus, it is
possible to detect multiple proteins (up to 30 different labels) in
the same tissue slide based on the different spectra yielded by
each label and even a quantification of a target molecules
becomes possible [137]. However, these more advanced Raman
techniques require a careful preparation [132] but they are supe-
rior compared to conventional Raman approaches due to their
enhanced sensitivity and selectivity.
Raman microspectroscopy enables the penetration into bio-
logical tissue up to several hundred microns in depth and
CARS, for example, has been successfully used to track metal
oxide and deuterated quaternary ammonium palmitoyl glycol
chitosan (dGCPQ) nanoparticles in fish and mice, respectively
[127,138]. Raman microscopy provides a valuable tool for
future applications in toxicopathological evaluation of NP due
to the independence of additional labels, the ease of quantifica-
tion of NP and the wide applicability on unstained tissue slides
as well as for bulk samples with no or only minimal sample
preparation [132,139]. However, Raman microspectroscopy has
several drawbacks. First, it is challenging to interpret the com-
plex and overlapping bands of Raman spectroscopy into mean-
ingful, biological information [140]. Another limitation is that
individual NP cannot be identified but they can only be local-
ized in their cellular context [138] due to the limited spatial
resolution of about 1 µm [130]. A further disadvantage is the
long time required for the acquisition of images covering larger
tissue areas [141]. For example, a typical scan area of Raman
microspectrometry is quite small with about 300 × 100 µm in
size. In order to acquire images with thousands of spectra, it
takes several hours to expose such a sample [132]. Moreover,
weak Raman signals may be overwhelmed by stronger autofluo-
rescent signals from the tissue sample itself. This can be
reduced by using NIR excitation light but the speed of data
acquisition is reduced and weak signals may be lost due to a
reduced sensitivity of NIR signals [141]. For a wider applica-
tion of label-free Raman microspectroscopy, it is desirable to
shorten the image acquisition. However, enhanced signal inten-
sities would be required for this [132]. To address these issues,
more advanced Raman techniques, including CARS, SERS and
SRS have been developed [140]. CARS imaging is faster
compared to the spontaneous Raman microspectroscopy but
special lasers as well as further processing tools are required to
translate the CARS spectrum to a Raman spectrum due to the
more complex CARS spectra. However, as a drawback of
CARS spectroscopy, a non-resonant background is usually
present [141]. SRS overcomes the latter two limitations of
CARS [140]. Furthermore, the accessibility of biological
samples for CARS is also limited due to high laser powers that
might destroy the sample as well as a high concentration of
certain molecules that are required [141].
Soft X-ray microscopy and spectromi-
croscopy
Soft X-ray microscopy techniques combine high spatial resolu-
tion in the few-nanometer range with chemical selectivity by
specific excitation processes and deep penetration into tissues.
A further advantage is that aqueous samples such as tissues can
be used without previous chemical fixation or other pretreat-
ment. Most frequently used is the so called water window above
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the carbon K-edge and below the O K-edge in which C and N
strongly absorb, whereas water is almost transparent. Conse-
quently, organic materials have an excellent contrast within this
range [142,143]. These requirements can be fulfilled by full-
field transmission X-ray microscopic techniques in the soft
regime and even tomographic analyses of biological samples of
up to 10 µm thickness are possible [143]. Besides high contrast
and penetration depth, synchrotron radiation in the soft X-ray
regime may be tuned for spectromicroscopy and chemical iden-
tification of the X-ray absorbing elements in biological samples
[143]. Soft X-ray spectromicroscopy techniques have been used
for probing protein interactions with model biomaterial surface
[142] and various quantitative analyses. At the C 1s edge the
detection limit of this technique is in the part per thousand
range [142] with a spatial resolution down to 10 nm [144].
The various capabilities of full-field transmission X-ray
microscopy (TXM) include 3D tomography, quantification of
absorption, and chemical identification through X-ray fluores-
cence and X-ray absorption near edge structure imaging [143].
Gold NP were visualized in mice by using full-field high-reso-
lution transmission X-ray microscopy combined with a potas-
sium permanganate staining of FFPE-tissue sections of the cere-
bellum and the liver [145]. Soft X-ray microscopy has been
successfully applied for 3D imaging of vitrified cells without
any further staining [146]. That study identified subcellular
compartments in adenocarcinoma cells in a significantly faster
and less laborious manner compared to 3D cryo-electron
tomography [146]. In addition, this approach may also be
applied for plunge-vitrified tissue in the future.
High-brilliance synchrotron radiation is tightly focused on a
sample in scanning transmission X-ray microscopy (STXM)
[147-149]. The sample is then raster-scanned while the inten-
sity of the transmitted X-rays is recorded, thus, a 2D image is
obtained. STXM has been used, for example, for studying cells
in vitro [144,150]. We used STXM for a penetration study on
gold core particles with silica shells with two sizes as well as
silica particles with a gold shell in excised human skin
(Figure 7) [151]. Following topical particle application, ultrami-
crotome sections of these samples were analyzed with light
microscopy and STXM (Figure 7). High resolution STXM
image analysis revealed single particles within the superficial
layer of the stratum corneum [151].
A combination of STXM with X-ray fluorescence (XRF) micro-
probe has been used to study the fate of zinc oxide nanoparti-
cles in vitro. Thereby, microfocused XRF elemental mapping
yielded the local distribution of zinc in the cells and micro-X-
ray absorption near-edge structure (XANES) spectroscopy
allowed for the identification of different zinc species present in
Figure 7: Light microscopy image (a) and scanning transmission X-ray
microscopy (STXM) image (b) of a hair follicle opening with a central
hair (H) at 270 eV of a 350 nm ultramicrotome section of human facial
skin incubated with silica particles (161 ± 13 nm) with a 42 ± 3 nm gold
core. Higher magnification of the STXM image visualized single parti-
cles (arrows) in an infundibulum on the surface and between corneo-
cytes (pound sign) of the stratum corneum (c).
the sample [144]. Others used STXM and compact source trans-
mission X-ray microscopy for subcellular imaging of vascular
smooth muscle cells and characterized the local calcium
distribution by using spectromicroscopy at the calcium L3,2
edges [150].
Despite the advantages of soft X-ray microscopy compared with
fluorescence or electron microscopy techniques, it has only
been applied for few biomedical samples so far due to the small
number of synchrotron radiation facilities worldwide.
Transmission electron microscopy (TEM)
To use an electron beam transmitting a sample can provide
significantly higher spatial resolution (down to 0.1 nm) and
higher magnifications by transmission electron microscopy
compared to all light microscopic methods described above. On
the one hand, TEM is still an important technique in the toxico-
logical assessment by pathologists. It provides detailed informa-
tion on subcellular structures regarding potentially toxicolog-
ical changes, for example, changes in size, structure or number
of cellular organelles highly responsive to all stress [152]. On
the other hand, the sample preparation is more laborious
and prone to artifacts compared to other microscopic
methods [152,153]. The time intensive tissue preparation and
analysis limit the analytical throughput of samples and result
in a small volume of 1 to 10 µm3 that is usually analyzed
[20,29,35,153,154]. Scanning transmission electron microscopy
(STEM) has been presented recently as an elegant approach to
overcome this limitation [154]. The authors simultaneously
recorded bright and dark field STEM images of gold NP in
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Figure 8: Transmission electron microscopic detection of single elec-
tron-dense SiO2-NP (55 ± 6 nm in diameter) between corneocytes
(asterisks) of the mouse skin (a). Higher magnification of the same
region (b) reveals single spherical nanoparticles (arrows). Sections
were prepared without uranyl acetate and lead citrate staining.
murine liver tissue using optimized contrast setting and thus
were able to analyze 243,000 μm3 of liver tissue in a single
setting [154].
Furthermore, the image interpretation of TEM is more chal-
lenging than that of light microscopic techniques [20,152].
Tissue responses to NP, such as inflammation, fibrosis or
necrosis [39,43,155] and endogenous structures, such as
collagen fibers or immune cell granules must be distinguished
from NP, requiring a deep understanding of normal and
diseased cellular ultrastructure which is the typical domain of a
pathologist [20].
Due to its high resolution, TEM is typically employed to visu-
alize single NP (Figure 8). However, a certain electron density
of the NP is required for this purpose. For example, organic NP
provide only low contrast in tissues, so that in general other
techniques are necessary to study these [56]. For the visualiza-
tion of electron-dense inorganic NP, for example, titanium
dioxide, SiO2-NP or QD, TEM has been widely used to charac-
terize the morphology and size of NP as well as their location in
tissues [28,35,39,113,156-158]. It has to be kept in mind,
however, that artifacts due to staining with lead citrate and
uranyl acetate can easily be misinterpreted as NP. To avoid or at
least reduce this risk, some authors preferred not to stain the
sample or used uranyl acetate only [29,159]. NP with a low
electron density, such as Raman-active-SiO2-NP or CNT, can
be labeled, for example, by synthesizing NP around a gold core
[154] or covalent binding of colloidal gold prior to their
employment in vivo [59] which increases their visibility in
TEM by enhanced contrast.
As a well-known artifact, the cell volume shrinks dramatically
during the standard preparation of electron microscopy samples,
mostly due to chemical fixation [160,161]. In addition, dehydra-
tion effects may deleteriously affect the ultrastructure of tissues
[162]. Therefore, cryogenic approaches in which chemical fixa-
tion is avoided and the normal hydration state is maintained
may be advantageous for a more life-like preservation of bio-
logical samples [163]. Cryo-TEM has been used to study skin
on the ultrastructural level [164], to characterize NP [165] and
for localizing NP in vitro [166].
As an additional technical refinement, qualitative elemental
analysis techniques can be performed on biological samples
following NP exposure by coupling a microanalysis system to
the electron microscope [35]. Energy dispersive X-ray (EDX)
analysis and electron energy loss spectroscopy (EELS) allow
one to identify the elemental composition of a sample
[167,168]. An elemental analysis may be of prime interest to
distinguish NP in the tissue from artifacts that may be produced
by staining procedures [35]. EDX analysis and EELS can be
combined with TEM as well as scanning electron microscopy
(SEM) and have been used for the detection of, for example,
titanium dioxide NP, QD, and silver NP [167,169-172]. In addi-
tion, a combination of EDX analysis with a scanning method
(STEM or SEM) allows for 2D-mapping of tissues or cells. As a
result, the distribution of specific elements such as phosphorus,
calcium and iron can be identified [173] and conclusions about
toxic effects induced by NP may be drawn.
In summary, TEM is thus regarded as a useful addition to a
series of microscopic tools, rather than a first-choice high-
throughput imaging technique for NP in tissues [20].
Scanning electron microscopy (SEM)
Imaging through scanning electron microscopy (SEM) is based
on a raster scan of an electron beam over a surface and the
detection of the backscattered electrons and the ejected second-
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Table 1: Comparison of analytical methods for the visualization of nanoparticles in the context of adjacent tissues.
method need for labeling major advantages major disadvantages
light microscopy in
FFPE tissues
depends on NP used easy, low cost, excellent evaluation of
pathomorpholgic effects in context of NP
detection
limited resolution (above 200 nm),
only for few NP species available as
imaging technique, staining





yes highly sensitive and specific, excellent
evaluation of pathomorphologic changes





yes, except for QD
and UCNP
easy, low cost, immunofluorescent
identification of target cells and subcellular
compartments possible, high specificity








yes, except for QD
and UCNP
high selectivity, differentiation of fluorescent
NP from autofluorescence, immunofluorescent
labeling of cells and compartments possible
with high numbers of different markers on one
slide
limited resolution (above 200 nm)
spectral unmixing yes, except for QD
and UCNP
easy, immunofluorescent labeling of cells and
compartments possible with high numbers of
different markers on one slide, high specificity,
differentiation of fluorescent NP from
autofluorescence




yes, except for QD
and UCNP
easy, immunofluorescent identification of
target cells and subcellular compartments
possible, high selectivity, improved resolution






no highly selective for chemical bonds within
tissue and cells, interactions of cells and NP
including chemical changes can be studied, no
or minimal sample preparation required












increased resolution compared to
fluorescence microscopy, high spatial
resolution (≥10 nm), element and site specific
method, no staining necessary, in situ
evaluation of changes of chemical composition
of NP, imaging of fully hydrated samples of up
to 10 µm thickness possible, correlated
imaging with CLSM and other light
microscopic techniques possible
significant technical effort required,
limited number of expertimental









high resolution (≥20 nm), 3D imaging,
evaluation of complete shock-frozen cells and
thick tissues samples, no changes of cells and
tissue due to embedding, slicing and
contrasting
technically demanding, limited






high resolution (down to 0.1 nm); detailed
information on subcellular changes and NP
structure, visualization of single NP,
combination with EDX or EELS allows for
elemental analysis within sample
only for electron-dense NP, time
intensive sample preparation and
analysis, staining and shrinking
artifacts (no shrinking in cryo-TEM),







high resolution (down to 1 nm), detailed
information of NP–cell interactions,
combination with EDX or EELS allows for
elemental analysis within sample
complex sample preparation,
technically demanding
ary electrons [174]. SEM can be combined with a transmission
electron detector for STEM or analytical methods, for example,
EDX or EELS as described for TEM. For example, SEM with
EDX analysis has been used to study the fate of silver NP and
ions in an in vitro human gastrointestinal digestion model [175].
Chemically or cryo-fixed tissue sections are often sputter-
coated, i.e., covered with a thin layer of conductive material, for
example, gold [176], to enhance the electrical conductivity of
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the specimen [177]. As an alternative, no coating of the spec-
imen is required when working with low-voltage SEM setups
[178]. High resolution SEM with a spatial resolution down to
1.3 nm [179] provides 3D images of nanoscale materials within
biological specimens [20]. Interactions between NP and the
surrounding cells can be well visualized and have been demon-
strated, for example, in lung sections following NP exposure
[34]. Here, it was possible to detect single multi-walled CNT
within alveolar macrophages and even when penetrating
through the mesothelial surface of the pleura following inhala-
tion in mice [180].
Chemical tissue fixation for SEM may have the same unfavor-
able shrinkage effects on cells and tissues as described for
TEM. To overcome this problem, a combination of fast-freezing
techniques such as high-pressure and plunge freezing has been
used for the ultrastructural examination of skin and other organs
without such artifacts [161,181,182]. In addition, cryo-SEM
has also been used for the concomitant localization of NP in
cells [183].
Conclusion
A toxicopathological evaluation of tissues is indispensable for
any risk assessment and hazard identification of NP [20]. Each
of the microscopic techniques reviewed here has its advantages
and limitations, as summarized in Table 1.
A single technique is often insufficient to address all questions
regarding the distribution of NP within the body, the cellular
uptake, and the target cells and organs. But a combination of
different detection methods may provide reliable information on
the NP biodistribution and associated histomorphologic
changes. Most of the techniques fail to detect single NP due to
limited resolution and thus may possess limited sensitivity.
Instead, many of these techniques may be more suitable for
toxicopathologic evaluations of the tissues.
Importantly, due to their limited resolution, the majority of
imaging techniques preferably used for localizing NP in tissue
context do not allow for an exact quantitative determination of
the number of nanoparticles in the tissues investigated. As a
simple approach, semiquantitative estimation of NP numbers in
tissues can be achieved by counting fluorescent spots or through
a pixel analysis [184,185]. For a precise quantification of NP,
however, spectroscopic or scintillation analyses may be
employed, as recently demonstrated [71]. For example, while
the authors failed to detect SiO2-NP in the liver and spleen by
fluorescence microscopy and TEM, elemental analysis by
inductively coupled plasma optical emission spectrometry (ICP-
OES) revealed elevated silica content in the organs compared to
a control group [28].
Taken together, for virtually all techniques described here, a
compromise has to be made between optical resolution and thus
sensitivity of NP detection and suitability for toxicological eval-
uation in a larger tissue context. The advantages and disadvan-
tages of each detection method must be weighed against each
other with regard to the study goal, nature of particles to be
detected, need for reliable histopathology, technical expertise
and equipment available.
Acknowledgements
No conflict of interests. This work was funded by the German
Research Foundation (DFG) Priority Program 1313 Biological
Responses to Nanoscale Particles Cluster NANO-SELECT, the
Leibniz Graduate School of Molecular Biophysics, the
Helmholtz Virtual Institute on “Multifunctional Polymers for
Medicine”, and the DFG SFB 1112 Projects B02, B03 and C03.
We thank Robert Brodwolf for helping with analysis of FLIM
image data. We further thank the MagForce AG, Berlin, for
kind permission to use images of iron oxide nanoparticles in the
glioblastoma tissue and Carl Zeiss AG for using their facilities
in Munich for SR-SIM and spectral imaging with linear
unmixing. Moreover, we thank Qi Gao as well as Jörg Raabe
for their support during the experiments with the scanning
transmission X-ray microscopy.
References
1. De Jong, W. H.; Borm, P. J. A. Int. J. Nanomed. 2008, 3, 133.
doi:10.2147/IJN.S596
2. Fischer, H. C.; Chan, W. C. W. Curr. Opin. Biotechnol. 2007, 18,
565–571. doi:10.1016/j.copbio.2007.11.008
3. Ballarre, J.; Desimone, P. M.; Chorro, M.; Baca, M.; Orellano, J. C.;
Ceré, S. M. J. Struct. Biol. 2013, 184, 164–172.
doi:10.1016/j.jsb.2013.09.016
4. Depan, D.; Misra, R. D. K. Mater. Sci. Eng., C 2014, 34, 221–228.
doi:10.1016/j.msec.2013.09.025
5. Fadeel, B.; Garcia-Bennett, A. E. Adv. Drug Delivery Rev. 2010, 62,
362–374. doi:10.1016/j.addr.2009.11.008
6. Dohan Ehrenfest, D. M.; Vazquez, L.; Park, Y.-J.; Sammartino, G.;
Bernard, J.-P. J. Oral Implantol. 2011, 37, 525–542.
doi:10.1563/aaid-joi-d-11-00080
7. Ryman-Rasmussen, J. P.; Riviere, J. E.; Monteiro-Riviere, N. A.
Toxicol. Sci. 2006, 91, 159–165. doi:10.1093/toxsci/kfj122
8. Matoba, T.; Egashira, K. Int. Heart J. 2014, 55, 281–286.
doi:10.1536/ihj.14-150
9. Underwood, C.; van Eps, A. W. Vet. J. 2012, 193, 12–23.
doi:10.1016/j.tvjl.2012.01.002
10. Ayres, J. G.; Borm, P.; Cassee, F. R.; Castranova, V.; Donaldson, K.;
Ghio, A.; Harrison, R. M.; Hider, R.; Kelly, F.; Kooter, I. M.;
Marano, F.; Maynard, R. L.; Mudway, I.; Nel, A.; Sioutas, C.;
Smith, S.; Baeza-Squiban, A.; Cho, A.; Duggan, S.; Froines, J.
Inhalation Toxicol. 2008, 20, 75–99. doi:10.1080/08958370701665517
11. Sayes, C. M.; Warheit, D. B.
Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2009, 1, 660–670.
doi:10.1002/wnan.58
Beilstein J. Nanotechnol. 2015, 6, 263–280.
276
12. Brandenberger, C.; Rowley, N. L.; Jackson-Humbles, D. N.;
Zhang, Q.; Bramble, L. A.; Lewandowski, R. P.; Wagner, J. G.;
Chen, W.; Kaplan, B. L.; Kaminski, N. E.; Baker, G. L.; Worden, R. M.;
Harkema, J. R. Part. Fibre Toxicol. 2013, 10, 26.
doi:10.1186/1743-8977-10-26
13. Hirai, T.; Yoshikawa, T.; Nabeshi, H.; Yoshida, T.; Tochigi, S.;
Ichihashi, K.-i.; Uji, M.; Akase, T.; Nagano, K.; Abe, Y.; Kamada, H.;
Itoh, N.; Tsunoda, S.-i.; Yoshioka, Y.; Tsutsumi, Y. Part. Fibre Toxicol.
2012, 9, 3. doi:10.1186/1743-8977-9-3
14. Hirai, T.; Yoshikawa, T.; Yoshida, T.; Ichihashi, K.-i.; Takahashi, H.;
Nabeshi, H.; Yoshioka, Y.; Tsutsumi, Y. Toxicol. Lett. 2012, 211,
S199. doi:10.1016/j.toxlet.2012.03.715
15. Wang, L.; Zhao, W.; Tan, W. Nano Res. 2008, 1, 99–115.
doi:10.1007/s12274-008-8018-3
16. Knopp, D.; Tang, D.; Niessner, R. Anal. Chim. Acta 2009, 647, 14–30.
doi:10.1016/j.aca.2009.05.037
17. Ostrowski, A.; Nordmeyer, D.; Mundhenk, L.; Fluhr, J. W.;
Lademann, J.; Graf, C.; Rühl, E.; Gruber, A. D. Nanoscale Res. Lett.
2014, 9, 524. doi:10.1186/1556-276X-9-524
18. Ilves, M.; Palomäki, J.; Vippola, M.; Lehto, M.; Savolainen, K.;
Savinko, T.; Alenius, H. Part. Fibre Toxicol. 2014, 11, 38.
doi:10.1186/s12989-014-0038-4
19. Papakostas, D.; Rancan, F.; Sterry, W.; Blume-Peytavi, U.; Vogt, A.
Arch. Dermatol. Res. 2011, 303, 533–550.
doi:10.1007/s00403-011-1163-7
20. Hubbs, A. F.; Sargent, L. M.; Porter, D. W.; Sager, T. M.; Chen, B. T.;
Frazer, D. G.; Castranova, V.; Sriram, K.; Nurkiewicz, T. R.;
Reynolds, S. H.; Battelli, L. A.; Schwegler-Berry, D.; McKinney, W.;
Fluharty, K. L.; Mercer, R. R. Toxicol. Pathol. 2013, 41, 395–409.
doi:10.1177/0192623312467403
21. Ettlin, R. A.; Bolon, B.; Pyrah, I.; Konishi, Y.; Black, H. E.
Exp. Toxicol. Pathol. 2008, 60, 1–8. doi:10.1016/j.etp.2008.03.001
22. ECVP European College of Veterinary Pathologists.
http://www.ecvpath.org/ (accessed Feb 23, 2014).
23. ACVP American College of Veterinary Pathologists.
http://www.acvp.org/index.cfm (accessed Feb 23, 2014).
24. Ruehl-Fehlert, C.; Bradley, A.; George, C.; Germann, P.-G.;
Provencher Bolliger, A.; Schulte, A. Exp. Toxicol. Pathol. 2005, 57,
1–5. doi:10.1016/j.etp.2005.03.001
25. Crissman, J. W.; Goodman, D. G.; Hildebrandt, P. K.;
Maronpot, R. R.; Prater, D. A.; Riley, J. H.; Seaman, W. J.;
Thake, D. C. Toxicol. Pathol. 2004, 32, 126–131.
doi:10.1080/01926230490268756
26. Sadrieh, N. FDA considerations for regulation of nanomaterial
containing products.
http://www.mhra.gov.uk/home/groups/comms-con/documents/website
resources/con2022823.pdf (accessed Feb 23, 2014).
27. Kramer, J. A.; Sagartz, J. E.; Morris, D. L. Nat. Rev. Drug Discovery
2007, 6, 636–649. doi:10.1038/nrd2378
28. Fu, C.; Liu, T.; Li, L.; Liu, H.; Chen, D.; Tang, F. Biomaterials 2013,
34, 2565–2575. doi:10.1016/j.biomaterials.2012.12.043
29. Adachi, K.; Yamada, N.; Yamamoto, K.; Yoshida, Y.; Yamamoto, O.
Nanotoxicology 2010, 4, 296–306. doi:10.3109/17435391003793095
30. Cho, W.-S.; Choi, M.; Han, B. S.; Cho, M.; Oh, J.; Park, K.; Kim, S. J.;
Kim, S. H.; Jeong, J. Toxicol. Lett. 2007, 175, 24–33.
doi:10.1016/j.toxlet.2007.09.008
31. Rancan, F.; Gao, Q.; Graf, C.; Troppens, S.; Hadam, S.;
Hackbarth, S.; Kembuan, C.; Blume-Peytavi, U.; Rühl, E.;
Lademann, J.; Vogt, A. ACS Nano 2012, 6, 6829–6842.
doi:10.1021/nn301622h
32. Vogt, A.; Combadiere, B.; Hadam, S.; Stieler, K. M.; Lademann, J.;
Schaefer, H.; Autran, B.; Sterry, W.; Blume-Peytavi, U.
J. Invest. Dermatol. 2006, 126, 1316–1322. doi:10.1038/sj.jid.5700226
33. Levenson, R.; Beechem, J.; McNamara, G. Anal. Cell. Pathol. 2012,
35, 339–361. doi:10.3233/ACP-2012-0062
34. Hubbs, A. F.; Mercer, R. R.; Benkovic, S. A.; Harkema, J.; Sriram, K.;
Schwegler-Berry, D.; Goravanahally, M. P.; Nurkiewicz, T. R.;
Castranova, V.; Sargent, L. M. Toxicol. Pathol. 2011, 39, 301–324.
doi:10.1177/0192623310390705
35. Marquis, B. J.; Love, S. A.; Braun, K. L.; Haynes, C. L. Analyst 2009,
134, 425–439. doi:10.1039/b818082b
36. Kittel, B.; Ruehl-Fehlert, C.; Morawietz, G.; Klapwijk, J.; Elwell, M. R.;
Lenz, B.; O'Sullivan, M. G.; Roth, D. R.; Wadsworth, P. F.
Exp. Toxicol. Pathol. 2004, 55, 413–431.
doi:10.1078/0940-2993-00349
37. Morawietz, G.; Ruehl-Fehlert, C.; Kittel, B.; Bube, A.; Keane, K.;
Halm, S.; Heuser, A.; Hellmann, J. Exp. Toxicol. Pathol. 2004, 55,
433–449. doi:10.1078/0940-2993-00350
38. Ruehl-Fehlert, C.; Kittel, B.; Morawietz, G.; Deslex, P.; Keenan, C.;
Mahrt, C. R.; Nolte, T.; Robinson, M.; Stuart, B. P.; Deschl, U.
Exp. Toxicol. Pathol. 2003, 55, 91–106. doi:10.1078/0940-2993-00311
39. Wu, J.; Liu, W.; Xue, C.; Zhou, S.; Lan, F.; Bi, L.; Xu, H.; Yang, X.;
Zeng, F.-D. Toxicol. Lett. 2009, 191, 1–8.
doi:10.1016/j.toxlet.2009.05.020
40. Nishimori, H.; Kondoh, M.; Isoda, K.; Tsunoda, S.-i.; Tsutsumi, Y.;
Yagi, K. Eur. J. Pharm. Biopharm. 2009, 72, 496–501.
doi:10.1016/j.ejpb.2009.02.005
41. Nishimori, H.; Kondoh, M.; Isoda, K.; Tsunoda, S.-i.; Tsutsumi, Y.;
Yagi, K. Eur. J. Pharm. Biopharm. 2009, 72, 626–629.
doi:10.1016/j.ejpb.2009.03.007
42. Isoda, K.; Hasezaki, T.; Kondoh, M.; Tsutsumi, Y.; Yagi, K. Pharmazie
2011, 66, 278–281. doi:10.1691/ph.2011.0808
43. Shvedova, A. A.; Kisin, E. R.; Mercer, R.; Murray, A. R.;
Johnson, V. J.; Potapovich, A. I.; Tyurina, Y. Y.; Gorelik, O.;
Arepalli, S.; Schwegler-Berry, D.; Hubbs, A. F.; Antonini, J.;
Evans, D. E.; Ku, B.-K.; Ramsey, D.; Maynard, A.; Kagan, V. E.;
Castranova, V.; Baron, P. Am. J. Physiol.: Lung Cell. Mol. Physiol.
2005, 289, L698–L708. doi:10.1152/ajplung.00084.2005
44. Porter, D. W.; Hubbs, A. F.; Mercer, R. R.; Wu, N.; Wolfarth, M. G.;
Sriram, K.; Leonard, S.; Battelli, L.; Schwegler-Berry, D.; Friend, S.;
Andrew, M.; Chen, B. T.; Tsuruoka, S.; Endo, M.; Castranova, V.
Toxicology 2010, 269, 136–147. doi:10.1016/j.tox.2009.10.017
45. van Landeghem, F. K. H.; Maier-Hauff, K.; Jordan, A.;
Hoffmann, K.-T.; Gneveckow, U.; Scholz, R.; Thiesen, B.; Brück, W.;
von Deimling, A. Biomaterials 2009, 30, 52–57.
doi:10.1016/j.biomaterials.2008.09.044
46. Johannsen, M.; Gneveckow, U.; Taymoorian, K.; Thiesen, B.;
Waldöfner, N.; Scholz, R.; Jung, K.; Jordan, A.; Wust, P.;
Loening, S. A. Int. J. Hyperthermia 2007, 23, 315–323.
doi:10.1080/02656730601175479
47. Jordan, A.; Scholz, R.; Maier-Hauff, K.; van Landeghem, F. H.;
Waldoefner, N.; Teichgraeber, U.; Pinkernelle, J.; Bruhn, H.;
Neumann, F.; Thiesen, B.; von Deimling, A.; Felix, R. J. Neuro-Oncol.
2006, 78, 7–14. doi:10.1007/s11060-005-9059-z
48. Stelter, L.; Pinkernelle, J.; Michel, R.; Schwartländer, R.;
Raschzok, N.; Morgul, M.; Koch, M.; Denecke, T.; Ruf, J.;
Bäumler, H.; Jordan, A.; Hamm, B.; Sauer, I.; Teichgräber, U.
Mol. Imaging Biol. 2010, 12, 25–34. doi:10.1007/s11307-009-0237-9
49. Santhosh, P. B.; Ulrih, N. P. Cancer Lett. 2013, 336, 8–17.
doi:10.1016/j.canlet.2013.04.032
Beilstein J. Nanotechnol. 2015, 6, 263–280.
277
50. Bumb, A.; Regino, C. A. S.; Egen, J. G.; Bernardo, M.; Dobson, P. J.;
Germain, R. N.; Choyke, P. L.; Brechbiel, M. W. Mol. Imaging Biol.
2011, 13, 1163–1172. doi:10.1007/s11307-010-0424-8
51. Bunting, H. Biotech. Histochem. 1949, 24, 109–115.
doi:10.3109/10520294909139590
52. Lev, R.; Spicer, S. S. J. Histochem. Cytochem. 1964, 12, 309.
doi:10.1177/12.4.309
53. Dorofeyev, A. E.; Vasilenko, I. V.; Rassokhina, O. A.;
Kondratiuk, R. B. Gastroenterol. Res. Pract. 2013, 2013, No. 431231.
doi:10.1155/2013/431231
54. Türk, H.; Haag, R.; Alban, S. Bioconjugate Chem. 2004, 15, 162–167.
doi:10.1021/bc034044j
55. Dernedde, J.; Rausch, A.; Weinhart, M.; Enders, S.; Tauber, R.;
Licha, K.; Schirner, M.; Zügel, U.; von Bonin, A.; Haag, R.
Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 19679–19684.
doi:10.1073/pnas.1003103107
56. Holzhausen, C.; Gröger, D.; Mundhenk, L.; Welker, P.; Haag, R.;
Gruber, A. D. Nanomedicine 2013, 9, 465–468.
doi:10.1016/j.nano.2013.02.003
57. Biffi, S.; Dal Monego, S.; Dullin, C.; Garrovo, C.; Bosnjak, B.;
Licha, K.; Welker, P.; Epstein, M. M.; Alves, F. PLoS One 2013, 8,
e57150. doi:10.1371/journal.pone.0057150
58. Gröger, D.; Paulus, F.; Licha, K.; Welker, P.; Weinhart, M.;
Holzhausen, C.; Mundhenk, L.; Gruber, A. D.; Abram, U.; Haag, R.
Bioconjugate Chem. 2013, 24, 1507–1514. doi:10.1021/bc400047f
59. Mercer, R. R.; Scabilloni, J.; Wang, L.; Kisin, E.; Murray, A. R.;
Schwegler-Berry, D.; Shvedova, A. A.; Castranova, V.
Am. J. Physiol.: Lung Cell. Mol. Physiol. 2008, 294, L87–L97.
doi:10.1152/ajplung.00186.2007
60. Oliver, C. Use of Immunogold with Silver Enhancement. In
Immunocytochemical Methods and Protocols; Oliver, C.;
Jamur, M. C., Eds.; Methods in Molecular Biology, Vol. 588; Humana
Press, 2010; pp 311–316. doi:10.1007/978-1-59745-324-0_30
61. Stojanov, K.; Zuhorn, I. S.; Dierckx, R. A. J. O.; de Vries, E. F. J.
Pharm. Res. 2012, 29, 3213–3234. doi:10.1007/s11095-012-0826-1
62. Huang, F.-Y.; Lee, T.-W.; Kao, C.-H. K.; Chang, C.-H.; Zhang, X.;
Lee, W.-Y.; Chen, W.-J.; Wang, S.-C.; Lo, J.-M.
Cancer Biother. Radiopharm. 2011, 26, 717–725.
doi:10.1089/cbr.2011.1052
63. Al-Sid-Cheikh, M.; Rouleau, C.; Pelletier, E. Mar. Environ. Res. 2013,
86, 21–28. doi:10.1016/j.marenvres.2013.02.003
64. Al-Hallak, M. H. D. K.; Sarfraz, M. K.; Azarmi, S.; Roa, W. H.;
Finlay, W. H.; Rouleau, C.; Löbenberg, R. Ther. Delivery 2012, 3,
725–734. doi:10.4155/tde.12.42
65. Lee, W.-C.; Hwang, J.-J.; Tseng, Y.-L.; Wang, H.-E.; Chang, Y.-F.;
Lu, Y.-C.; Ting, G.; Whang-Peng, J.; Wang, S.-J.
Nucl. Instrum. Methods Phys. Res., Sect. A 2006, 569, 497–504.
doi:10.1016/j.nima.2006.08.135
66. Sakamoto, A.; Ido, T. Brain Res. 1993, 629, 171–175.
doi:10.1016/0006-8993(93)90499-D
67. Dassler, K.; Roohi, F.; Lohrke, J.; Ide, A.; Remmele, S.; Hütter, J.;
Pietsch, H.; Pison, U.; Schütz, G. Invest. Radiol. 2012, 47, 383–391.
doi:10.1097/RLI.0b013e31824c5a57
68. Barthe, N.; Chatti, K.; Coulon, P.; Maîtrejean, S.; Basse-Cathalinat, B.
Nucl. Instrum. Methods Phys. Res., Sect. A 2004, 527, 41–45.
doi:10.1016/j.nima.2004.03.014
69. Gahan, P., Ed. Autoradiography for Biologists; Academic Press:
London, United Kingdom, 1972.
70. Santini, M. A.; Ratner, C.; Aznar, S.; Klein, A. B.; Knudsen, G. M.;
Mikkelsen, J. D. J. Neurosci. Res. 2013, 91, 634–641.
doi:10.1002/jnr.23198
71. Caro, L. G.; van Tubergen, R. P. J. Cell Biol. 1962, 15, 173–188.
doi:10.1083/jcb.15.2.173
72. Kennel, S. J.; Woodward, J. D.; Rondinone, A. J.; Wall, J.; Huang, Y.;
Mirzadeh, S. Nucl. Med. Biol. 2008, 35, 501–514.
doi:10.1016/j.nucmedbio.2008.02.001
73. Kner, P.; Chhun, B. B.; Griffis, E. R.; Winoto, L.; Gustafsson, M. G. L.
Nat. Methods 2009, 6, 339–342. doi:10.1038/nmeth.1324
74. Blaise, S.; Kneib, M.; Rousseau, A.; Gambino, F.; Chenard, M.-P.;
Messadeq, N.; Muckenstrum, M.; Alpy, F.; Tomasetto, C.;
Humeau, Y.; Rio, M.-C. PLoS One 2012, 7, e30917.
doi:10.1371/journal.pone.0030917
75. Cho, M.; Cho, W.-S.; Choi, M.; Kim, S. J.; Han, B. S.; Kim, S. H.;
Kim, H. O.; Sheen, Y. Y.; Jeong, J. Toxicol. Lett. 2009, 189, 177–183.
doi:10.1016/j.toxlet.2009.04.017
76. Gopee, N. V.; Roberts, D. W.; Webb, P.; Cozart, C. R.; Siitonen, P. H.;
Warbritton, A. R.; Yu, W. W.; Colvin, V. L.; Walker, N. J.;
Howard, P. C. Toxicol. Sci. 2007, 98, 249–257.
doi:10.1093/toxsci/kfm074
77. Gopee, N. V.; Roberts, D. W.; Webb, P.; Cozart, C. R.; Siitonen, P. H.;
Latendresse, J. R.; Warbitton, A. R.; Yu, W. W.; Colvin, V. L.;
Walker, N. J.; Howard, P. C. Toxicol. Sci. 2009, 111, 37–48.
doi:10.1093/toxsci/kfp139
78. Chu, M.; Wu, Q.; Wang, J.; Hou, S.; Miao, Y.; Peng, J.; Sun, Y.
Nanotechnology 2007, 18, 455103.
doi:10.1088/0957-4484/18/45/455103
79. Graf, C.; Gao, Q.; Schütz, I.; Noufele, C. N.; Ruan, W.; Posselt, U.;
Korotianskiy, E.; Nordmeyer, D.; Rancan, F.; Hadam, S.; Vogt, A.;
Lademann, J.; Haucke, V.; Rühl, E. Langmuir 2012, 28, 7598–7613.
doi:10.1021/la204913t
80. Nabeshi, H.; Yoshikawa, T.; Matsuyama, K.; Nakazato, Y.;
Matsuo, K.; Arimori, A.; Isobe, M.; Tochigi, S.; Kondoh, S.; Hirai, T.;
Akase, T.; Yamashita, T.; Yamashita, K.; Yoshida, T.; Nagano, K.;
Abe, Y.; Yoshioka, Y.; Kamada, H.; Imazawa, T.; Itoh, N.;
Nakagawa, S.; Mayumi, T.; Tsunoda, S.-i.; Tsutsumi, Y. Biomaterials
2011, 32, 2713–2724. doi:10.1016/j.biomaterials.2010.12.042
81. Ostrowski, A.; Nordmeyer, D.; Boreham, A.; Brodwolf, R.;
Mundhenk, L.; Fluhr, J. W.; Lademann, J.; Graf, C.; Rühl, E.;
Alexiev, U.; Gruber, A. D. Nanomedicine 2014, 10, 1571–1581.
doi:10.1016/j.nano.2014.04.004
82. Boreham, A.; Kim, T.-Y.; Spahn, V.; Stein, C.; Mundhenk, L.;
Gruber, A. D.; Haag, R.; Welker, P.; Licha, K.; Alexiev, U.
ACS Med. Chem. Lett. 2011, 2, 724–728. doi:10.1021/ml200092m
83. Choi, J.; Burns, A. A.; Williams, R. M.; Zhou, Z.; Flesken-Nikitin, A.;
Zipfel, W. R.; Wiesner, U.; Nikitin, A. Y. J. Biomed. Opt. 2007, 12,
064007. doi:10.1117/1.2823149
84. Ow, H.; Larson, D. R.; Srivastava, M.; Baird, B. A.; Webb, W. W.;
Wiesner, U. Nano Lett. 2005, 5, 113–117. doi:10.1021/nl0482478
85. Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferrari, M.;
Fuchs, H. Angew. Chem., Int. Ed. 2009, 48, 872–897.
doi:10.1002/anie.200802585
86. Medintz, I. L.; Uyeda, H. T.; Goldman, E. R.; Mattoussi, H. Nat. Mater.
2005, 4, 435–446. doi:10.1038/nmat1390
87. Kim, S.; Lim, Y. T.; Soltesz, E. G.; De Grand, A. M.; Lee, J.;
Nakayama, A.; Parker, J. A.; Mihaljevic, T.; Laurence, R. G.;
Dor, D. M.; Cohn, L. H.; Bawendi, M. G.; Frangioni, J. V.
Nat. Biotechnol. 2004, 22, 93–97. doi:10.1038/nbt920
Beilstein J. Nanotechnol. 2015, 6, 263–280.
278
88. Graf, C.; Dembski, S.; Hofmann, A.; Rühl, E. Langmuir 2006, 22,
5604–5610. doi:10.1021/la060136w
89. Gerion, D.; Pinaud, F.; Williams, S. C.; Parak, W. J.; Zanchet, D.;
Weiss, S.; Alivisatos, A. P. J. Phys. Chem. B 2001, 105, 8861–8871.
doi:10.1021/jp0105488
90. Dembski, S.; Graf, C.; Krüger, T.; Gbureck, U.; Ewald, A.; Bock, A.;
Rühl, E. Small 2008, 4, 1516–1526. doi:10.1002/smll.200700997
91. Haase, M.; Schäfer, H. Angew. Chem., Int. Ed. 2011, 50, 5808–5829.
doi:10.1002/anie.201005159
92. Wang, F.; Liu, X. Chem. Soc. Rev. 2009, 38, 976–989.
doi:10.1039/b809132n
93. Gorris, H. H.; Wolfbeis, O. S. Angew. Chem., Int. Ed. 2013, 52,
3584–3600. doi:10.1002/anie.201208196
94. Choi, H. S.; Ashitate, Y.; Lee, J. H.; Kim, S. H.; Matsui, A.; Insin, N.;
Bawendi, M. G.; Semmler-Behnke, M.; Frangioni, J. V.; Tsuda, A.
Nat. Biotechnol. 2010, 28, 1300–1303. doi:10.1038/nbt.1696
95. Lee, C.-M.; Jeong, H.-J.; Yun, K.-N.; Kim, D. W.; Sohn, M.-H.;
Lee, J. K.; Jeong, J.; Lim, S. T. Int. J. Nanomed. 2012, 7, 3203.
doi:10.2147/IJN.S32828
96. Cheon, J.; Lee, J.-H. Acc. Chem. Res. 2008, 41, 1630–1640.
doi:10.1021/ar800045c
97. Cheng, S.-H.; Li, F.-C.; Souris, J. S.; Yang, C.-S.; Tseng, F.-G.;
Lee, H.-S.; Chen, C.-T.; Dong, C.-Y.; Lo, L.-W. ACS Nano 2012, 6,
4122–4131. doi:10.1021/nn300558p
98. van Schooneveld, M. M.; Vucic, E.; Koole, R.; Zhou, Y.; Stocks, J.;
Cormode, D. P.; Tang, C. Y.; Gordon, R. E.; Nicolay, K.; Meijerink, A.;
Fayad, Z. A.; Mulder, W. J. M. Nano Lett. 2008, 8, 2517–2525.
doi:10.1021/nl801596a
99. Bastiaens, P. I. H.; Squire, A. Trends Cell Biol. 1999, 9, 48–52.
doi:10.1016/S0962-8924(98)01410-X
100.Alexiev, U.; Rimke, I.; Pöhlmann, T. J. Mol. Biol. 2003, 328, 705–719.
doi:10.1016/S0022-2836(03)00326-7
101.Alexiev, U.; Farrens, D. L. Biochim. Biophys. Acta 2014, 1837,
694–709. doi:10.1016/j.bbabio.2013.10.008
102.Festy, F.; Ameer-Beg, S. M.; Ng, T.; Suhling, K. Mol. BioSyst. 2007, 3,
381–391. doi:10.1039/b617204k
103.Boreham, A.; Brodwolf, R.; Pfaff, M.; Kim, T.-Y.; Schlieter, T.;
Mundhenk, L.; Gruber, A. D.; Gröger, D.; Licha, K.; Haag, R.;
Alexiev, U. Polym. Adv. Technol. 2014, 25, 1329–1336.
doi:10.1002/pat.3355
104.Roberts, M. S.; Roberts, M. J.; Robertson, T. A.; Sanchez, W.;
Thörling, C.; Zou, Y.; Zhao, X.; Becker, W.; Zvyagin, A. V.
J. Biophotonics 2008, 1, 478–493. doi:10.1002/jbio.200810058
105.Levenson, R. M.; Mansfield, J. R. Cytometry, Part A 2006, 69A,
748–758. doi:10.1002/cyto.a.20319
106.Prow, T. W.; Grice, J. E.; Lin, L. L.; Faye, R.; Butler, M.; Becker, W.;
Wurm, E. M. T.; Yoong, C.; Robertson, T. A.; Soyer, H. P.;
Roberts, M. S. Adv. Drug Delivery Rev. 2011, 63, 470–491.
doi:10.1016/j.addr.2011.01.012
107.Alnasif, N.; Zoschke, C.; Fleige, E.; Brodwolf, R.; Boreham, A.;
Rühl, E.; Eckl, K.-M.; Merk, H.-F.; Hennies, H. C.; Alexiev, U.;
Haag, R.; Küchler, S.; Schäfer-Korting, M. J. Controlled Release
2014, 185, 45–50. doi:10.1016/j.jconrel.2014.04.006
108.Zimmermann, T. Spectral Imaging and Linear Unmixing in Light
Microscopy. In Microscopy Techniques; Rietdorf, J., Ed.; Advances in
Biochemical Engineering, Vol. 95; Springer: Berlin, Germany, 2005;
pp 245–265. doi:10.1007/b102216
109.Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S.
Nat. Biotechnol. 2004, 22, 969–976. doi:10.1038/nbt994
110.Zimmermann, T.; Rietdorf, J.; Pepperkok, R. FEBS Lett. 2003, 546,
87–92. doi:10.1016/S0014-5793(03)00521-0
111.Mansfield, J. R.; Hoyt, C.; Levenson, R. M. Visualization of
Microscopy-Based Spectral Imaging Data from Multi-Label Tissue
Sections. Current Protocols in Molecular Biology; John Wiley & Sons,
2001. doi:10.1002/0471142727.mb1419s84
112.Mansfield, J. R. Med. Lab. Obs. 2014, 46, 12–13.
113.Mortensen, L. J.; Oberdörster, G.; Pentland, A. P.; DeLouise, L. A.
Nano Lett. 2008, 8, 2779–2787. doi:10.1021/nl801323y
114.Levenson, R. M.; Lynch, D. T.; Kobayashi, H.; Backer, J. M.;
Backer, M. V. ILAR J. 2008, 49, 78–88. doi:10.1093/ilar.49.1.78
115.Gustafsson, M. G. L. J. Microsc. (Oxford, U. K.) 2000, 198, 82–87.
doi:10.1046/j.1365-2818.2000.00710.x
116.Gustafsson, M. G. L. Proc. Natl. Acad. Sci. U. S. A. 2005, 102,
13081–13086. doi:10.1073/pnas.0406877102
117.Habuchi, S. Front. Bioeng. Biotechnol. 2014, 2.
doi:10.3389/fbioe.2014.00020
118.Heintzmann, R.; Gustafsson, M. G. L. Nat. Photonics 2009, 3,
362–364. doi:10.1038/nphoton.2009.102
119.York, A. G.; Chandris, P.; Nogare, D. D.; Head, J.; Wawrzusin, P.;
Fischer, R. S.; Chitnis, A.; Shroff, H. Nat. Methods 2013, 10,
1122–1126. doi:10.1038/nmeth.2687
120.Gustafsson, M. G. L.; Shao, L.; Carlton, P. M.; Wang, C. J. R.;
Golubovskaya, I. N.; Cande, W. Z.; Agard, D. A.; Sedat, J. W.
Biophys. J. 2008, 94, 4957–4970. doi:10.1529/biophysj.107.120345
121.Schermelleh, L.; Carlton, P. M.; Haase, S.; Shao, L.; Winoto, L.;
Kner, P.; Burke, B.; Cardoso, M. C.; Agard, D. A.;
Gustafsson, M. G. L.; Leonhardt, H.; Sedat, J. W. Science 2008, 320,
1332–1336. doi:10.1126/science.1156947
122.Leung, B. O.; Chou, K. C. Appl. Spectrosc. 2011, 65, 967–980.
doi:10.1366/11-06398
123.Min, J.; Jang, J.; Keum, D.; Ryu, S.-W.; Choi, C.; Jeong, K.-H.;
Ye, J. C. Sci. Rep. 2013, 3, No. 2075. doi:10.1038/srep02075
124.Fernández-Suárez, M.; Ting, A. Y. Nat. Rev. Mol. Cell Biol. 2008, 9,
929–943. doi:10.1038/nrm2531
125.Lidke, K.; Rieger, B.; Jovin, T.; Heintzmann, R. Opt. Express 2005,
13, 7052–7062. doi:10.1364/opex.13.007052
126.Chernenko, T.; Mätthaus, C.; Milane, L.; Quintero, L.; Amiji, M.;
Diem, M. ACS Nano 2009, 3, 3552–3559. doi:10.1021/nn9010973
127.Garrett, N. L.; Lalatsa, A.; Uchegbu, I.; Schätzlein, A.; Moger, J.
J. Biophotonics 2012, 5, 458–468. doi:10.1002/jbio.201200006
128.Rodriguez, L. G.; Lockett, S. J.; Holtom, G. R. Cytometry, Part A
2006, 69A, 779–791. doi:10.1002/cyto.a.20299
129.Chernenko, T.; Buyukozturk, F.; Miljkovic, M.; Carrier, R.; Diem, M.;
Amiji, M. Drug Delivery Transl. Res. 2013, 3, 575–586.
doi:10.1007/s13346-013-0178-3
130.Wartewig, S.; Neubert, R. H. H. Adv. Drug Delivery Rev. 2005, 57,
1144–1170. doi:10.1016/j.addr.2005.01.022
131.Nijssen, A.; Koljenović, S.; Schut, T. C. B.; Caspers, P. J.;
Puppels, G. J. J. Biophotonics 2009, 2, 29–36.
doi:10.1002/jbio.200810055
132.Krafft, C.; Dietzek, B.; Popp, J. Analyst 2009, 134, 1046–1057.
doi:10.1039/b822354h
133.Cialla, D.; März, A.; Böhme, R.; Theil, F.; Weber, K.; Schmitt, M.;
Popp, J. Anal. Bioanal. Chem. 2012, 403, 27–54.
doi:10.1007/s00216-011-5631-x
134.Belsey, N. A.; Garrett, N. L.; Contreras-Rojas, L. R.;
Pickup-Gerlaugh, A. J.; Price, G. J.; Moger, J.; Guy, R. H.
J. Controlled Release 2014, 174, 37–42.
doi:10.1016/j.jconrel.2013.11.002
Beilstein J. Nanotechnol. 2015, 6, 263–280.
279
135.Freudiger, C. W.; Min, W.; Saar, B. G.; Lu, S.; Holtom, G. R.; He, C.;
Tsai, J. C.; Kang, J. X.; Xie, X. S. Science 2008, 322, 1857–1861.
doi:10.1126/science.1165758
136.König, K.; Breunig, H. G.; Bückle, R.; Kellner-Höfer, M.; Weinigel, M.;
Büttner, E.; Sterry, W.; Lademann, J. Laser Phys. Lett. 2011, 8, 465.
doi:10.1002/lapl.201110014
137.Schlücker, S. ChemPhysChem 2009, 10, 1344–1354.
doi:10.1002/cphc.200900119
138.Moger, J.; Johnston, B. D.; Tyler, C. R. Opt. Express 2008, 16,
3408–3419. doi:10.1364/oe.16.003408
139.Hanlon, E. B.; Manoharan, R.; Koo, T. W.; Shafer, K. E.; Motz, J. T.;
Fitzmaurice, M.; Kramer, J. R.; Itzkan, I.; Dasari, R. R.; Feld, M. S.
Phys. Med. Biol. 2000, 45, R1. doi:10.1088/0031-9155/45/2/201
140.Li, M.; Xu, J.; Romero-Gonzalez, M.; Banwart, S. A.; Huang, W. E.
Curr. Opin. Biotechnol. 2012, 23, 56–63.
doi:10.1016/j.copbio.2011.11.019
141.Krafft, C.; Dietzek, B.; Schmitt, M.; Popp, J. J. Biomed. Opt. 2012, 17,
040801. doi:10.1117/1.JBO.17.4.040801
142.Leung, B. O.; Brash, J. L.; Hitchcock, A. P. Materials 2010, 3,
3911–3938. doi:10.3390/ma3073911
143.Andrews, J. C.; Meirer, F.; Liu, Y.; Mester, Z.; Pianetta, P.
Microsc. Res. Tech. 2011, 74, 671–681. doi:10.1002/jemt.20907
144.Gilbert, B.; Fakra, S. C.; Xia, T.; Pokhrel, S.; Mädler, L.; Nel, A. E.
ACS Nano 2012, 6, 4921–4930. doi:10.1021/nn300425a
145.Chien, C.-C.; Cheng, C.-C.; Chen, H. H.; Hwu, Y.; Chu, Y. S.;
Petibois, C.; Chen, A.; Ching, Y.-T.; Margaritondo, G.
Anal. Bioanal. Chem. 2012, 404, 1287–1296.
doi:10.1007/s00216-012-6217-y
146.Schneider, G.; Guttmann, P.; Heim, S.; Rehbein, S.; Mueller, F.;
Nagashima, K.; Heymann, J. B.; Müller, W. G.; McNally, J. G.
Nat. Methods 2010, 7, 985–987. doi:10.1038/nmeth.1533
147.Hitchcock, A. P.; Dynes, J. J.; Johansson, G.; Wang, J.; Botton, G.
Micron 2008, 39, 311–319. doi:10.1016/j.micron.2007.09.008
148.Ade, H.; Hitchcock, A. P. Polymer 2008, 49, 643–675.
doi:10.1016/j.polymer.2007.10.030
149.Eichert, D.; Gregoratti, L.; Kaulich, B.; Marcello, A.; Melpignano, P.;
Quaroni, L.; Kiskinova, M. Anal. Bioanal. Chem. 2007, 389,
1121–1132. doi:10.1007/s00216-007-1532-4
150.Sedlmair, J.; Gleber, S.-C.; Mert, S. Ö.; Bertilson, M.; von Hofsten, O.;
Thieme, J.; Pfohl, T. Microsc. Microanal. 2011, 17, 991–1001.
doi:10.1017/S1431927611012165
151.Graf, C.; Meinke, M.; Gao, Q.; Hadam, S.; Raabe, J.; Sterry, W.;
Blume-Peytavi, U.; Lademann, J.; Rühl, E.; Vogt, A. J. Biomed. Opt.
2009, 14, 021015. doi:10.1117/1.3078811
152.Fagerland, J. A.; Wall, H. G.; Pandher, K.; LeRoy, B. E.; Gagne, G. D.
Toxicol. Pathol. 2012, 40, 391–402. doi:10.1177/0192623311430239
153.Gontier, E.; Ynsa, M.-D.; Bíró, T.; Hunyadi, J.; Kiss, B.; Gáspár, K.;
Pinheiro, T.; Silva, J.-N.; Filipe, P.; Stachura, J.; Dabros, W.;
Reinert, T.; Butz, T.; Moretto, P.; Surlève-Bazeille, J.-E.
Nanotoxicology 2008, 2, 218–231. doi:10.1080/17435390802538508
154.Kempen, P. J.; Thakor, A. S.; Zavaleta, C.; Gambhir, S. S.; Sinclair, R.
Microsc. Microanal. 2013, 19, 1290–1297.
doi:10.1017/S143192761300192X
155.Mercer, R. R.; Hubbs, A. F.; Scabilloni, J. F.; Wang, L.; Battelli, L. A.;
Friend, S.; Castranova, V.; Porter, D. W. Part. Fibre Toxicol. 2011, 8,
21. doi:10.1186/1743-8977-8-21
156.Samberg, M. E.; Oldenburg, S. J.; Monteiro-Riviere, N. A.
Environ. Health Perspect. 2010, 118, 407–413.
doi:10.1289/ehp.0901398
157.Yamashita, K.; Yoshioka, Y.; Higashisaka, K.; Mimura, K.;
Morishita, Y.; Nozaki, M.; Yoshida, T.; Ogura, T.; Nabeshi, H.;
Nagano, K.; Abe, Y.; Kamada, H.; Monobe, Y.; Imazawa, T.;
Aoshima, H.; Shishido, K.; Kawai, Y.; Mayumi, T.; Tsunoda, S.-i.;
Itoh, N.; Yoshikawa, T.; Yanagihara, I.; Saito, S.; Tsutsumi, Y.
Nat. Nanotechnol. 2011, 6, 321–328. doi:10.1038/nnano.2011.41
158.Petri-Fink, A.; Steitz, B.; Finka, A.; Salaklang, J.; Hofmann, H.
Eur. J. Pharm. Biopharm. 2008, 68, 129–137.
doi:10.1016/j.ejpb.2007.02.024
159.Haase, A.; Rott, S.; Mantion, A.; Graf, P.; Plendl, J.;
Thünemann, A. F.; Meier, W. P.; Taubert, A.; Luch, A.; Reiser, G.
Toxicol. Sci. 2012, 126, 457–468. doi:10.1093/toxsci/kfs003
160.Droste, M. S.; Biel, S. S.; Terstegen, L.; Wittern, K.-P.; Wenck, H.;
Wepf, R. J. Biomed. Opt. 2005, 10, 064017. doi:10.1117/1.2138011
161.Richter, T.; Biel, S. S.; Sattler, M.; Wenck, H.; Wittern, K. P.;
Wiesendanger, R.; Wepf, R. J. J. Microsc. (Oxford, U. K.) 2007, 225,
201–207. doi:10.1111/j.1365-2818.2007.01732.x
162.Echlin, P. Low-temperature microscopy and analysis; Springer: Berlin,
Germany, 1992. doi:10.1007/978-1-4899-2302-8
163.Lucas, M. S.; Günthert, M.; Gasser, P.; Lucas, F.; Wepf, R. Bridging
Microscopes: 3D Correlative Light and Scanning Electron Microscopy
of Complex Biological Structures. In Correlative Light and Electron
MIcroscopy; Thomas, M.-R.; Paul, V., Eds.; Methods Cell Biol., Vol.
111; Academic Press, 2012; pp 325–356.
doi:10.1016/B978-0-12-416026-2.00017-0
164.Norlén, L. Int. J. Cosmet. Sci. 2007, 29, 335–352.
doi:10.1111/j.1468-2494.2007.00395.x
165.Kuntsche, J.; Horst, J. C.; Bunjes, H. Int. J. Pharm. 2011, 417,
120–137. doi:10.1016/j.ijpharm.2011.02.001
166.Kunisawa, J.; Masuda, T.; Katayama, K.; Yoshikawa, T.; Tsutsumi, Y.;
Akashi, M.; Mayumi, T.; Nakagawa, S. J. Controlled Release 2005,
105, 344–353. doi:10.1016/j.jconrel.2005.03.020
167.Iannuccelli, V.; Coppi, G.; Romagnoli, M.; Sergi, S.; Leo, E.
Int. J. Pharm. 2013, 447, 204–212. doi:10.1016/j.ijpharm.2013.03.002
168.Egerton, R. F. Rep. Prog. Phys. 2009, 72, 016502.
doi:10.1088/0034-4885/72/1/016502
169.Jeong, S. H.; Kim, J. H.; Yi, S. M.; Lee, J. P.; Kim, J. H.; Sohn, K. H.;
Park, K. L.; Kim, M.-K.; Son, S. W. Biochem. Biophys. Res. Commun.
2010, 394, 612–615. doi:10.1016/j.bbrc.2010.03.032
170.George, R.; Merten, S.; Wang, T. T.; Kennedy, P.; Maitz, P.
Australas. J. Dermatol. 2014, 55, 185–190. doi:10.1111/ajd.12101
171.Asharani, P. V.; Wu, Y. L.; Gong, Z.; Valiyaveettil, S. Nanotechnology
2008, 19, 255102. doi:10.1088/0957-4484/19/25/255102
172.Patri, A.; Umbreit, T.; Zheng, J.; Nagashima, K.; Goering, P.;
Francke-Carroll, S.; Gordon, E.; Weaver, J.; Miller, T.; Sadrieh, N.;
McNeil, S.; Stratmeyer, M. J. Appl. Toxicol. 2009, 29, 662–672.
doi:10.1002/jat.1454
173.Sousa, A. A.; Leapman, R. D. Ultramicroscopy 2012, 123, 38–49.
doi:10.1016/j.ultramic.2012.04.005
174.Pawley, J. Scanning 1997, 19, 324–336.
175.Walczak, A. P.; Fokkink, R.; Peters, R.; Tromp, P.;
Herrera Rivera, Z. E.; Rietjens, I. M. C. M.; Hendriksen, P. J. M.;
Bouwmeester, H. Nanotoxicology 2013, 7, 1198–1210.
doi:10.3109/17435390.2012.726382
176.Købler, C.; Saber, A. T.; Jacobsen, N. R.; Wallin, H.; Vogel, U.;
Qvortrup, K.; Mølhave, K. Anal. Bioanal. Chem. 2014, 406,
3863–3873. doi:10.1007/s00216-013-7566-x
177.Muscariello, L.; Rosso, F.; Marino, G.; Giordano, A.; Barbarisi, M.;
Cafiero, G.; Barbarisi, A. J. Cell. Physiol. 2005, 205, 328–334.
doi:10.1002/jcp.20444
Beilstein J. Nanotechnol. 2015, 6, 263–280.
280
178.Chang, H.-H.; Cheng, C.-L.; Huang, P.-J.; Lin, S.-Y.
Anal. Bioanal. Chem. 2014, 406, 359–366.
doi:10.1007/s00216-013-7414-z




(accessed Feb 25, 2014).
180.Mercer, R. R.; Hubbs, A. F.; Scabilloni, J. F.; Wang, L.; Battelli, L. A.;
Schwegler-Berry, D.; Castranova, V.; Porter, D. W. Part. Fibre Toxicol.
2010, 7, 28. doi:10.1186/1743-8977-7-28
181.Richter, T.; Peuckert, C.; Sattler, M.; Koenig, K.; Riemann, I.;
Hintze, U.; Wittern, K.-P.; Wiesendanger, R.; Wepf, R.
Skin Pharmacol. Physiol. 2004, 17, 246–257. doi:10.1159/000080218
182.Sung, B.; Kim, M. S.; Lee, B.-C.; Yoo, J. S.; Lee, S.-H.; Kim, Y.-J.;
Kim, K.-W.; Soh, K.-S. Naturwissenschaften 2008, 95, 117–124.
doi:10.1007/s00114-007-0300-9
183.Win, K. Y.; Feng, S.-S. Biomaterials 2005, 26, 2713–2722.
doi:10.1016/j.biomaterials.2004.07.050
184.Mahe, B.; Vogt, A.; Liard, C.; Duffy, D.; Abadie, V.; Bonduelle, O.;
Boissonnas, A.; Sterry, W.; Verrier, B.; Blume-Peytavi, U.;
Combadiere, B. J. Invest. Dermatol. 2008, 129, 1156–1164.
doi:10.1038/jid.2008.356
185.Labouta, H. I.; Kraus, T.; El-Khordagui, L. K.; Schneider, M.
Int. J. Pharm. 2011, 413, 279–282. doi:10.1016/j.ijpharm.2011.03.067
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of
Nanotechnology terms and conditions:
(http://www.beilstein-journals.org/bjnano)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjnano.6.25
